{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:17:37Z","timestamp":1793848657824,"version":"4.6.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","aaojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ophtha.2016.09.020","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T19:03:09Z","timestamp":1478199789000},"page":"123-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Orbital\/Periorbital Plexiform Neurofibromas in Children with Neurofibromatosis Type 1"],"prefix":"10.1016","volume":"124","author":[{"given":"Robert A.","family":"Avery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Katowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gena","family":"Heidary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Dombi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte C.","family":"Widemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly A.","family":"Hutcheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Madigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Listernick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant T.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry E.","family":"Berland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond J.","family":"FitzGibbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Korf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2016.09.020_bib1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0733-8619(01)00019-6","article-title":"Neurofibromatosis 1","volume":"20","author":"Lynch","year":"2002","journal-title":"Neurol Clin"},{"key":"10.1016\/j.ophtha.2016.09.020_bib2","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S1474-4422(07)70075-3","article-title":"Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective","volume":"6","author":"Ferner","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ophtha.2016.09.020_bib3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ophtha.2011.07.046","article-title":"Choroidal abnormalities detected by near-infrared reflectance imaging as a new diagnostic criterion for neurofibromatosis 1","volume":"119","author":"Viola","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.09.020_bib4","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0161-6420(84)34288-9","article-title":"Congenital ectropion uveae with glaucoma","volume":"91","author":"Ritch","year":"1984","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.09.020_bib5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/ceo.12179","article-title":"Long-term visual outcomes in patients with orbitotemporal neurofibromatosis","volume":"42","author":"Greenwell","year":"2014","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.020_bib6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/WNO.0b013e31822aef82","article-title":"Optic pathway gliomas","volume":"31","author":"Avery","year":"2011","journal-title":"J\u00a0Neuroophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.020_bib7","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.ajo.2013.01.011","article-title":"Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromas","volume":"155","author":"Avery","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.020_bib8","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.ophtha.2012.04.032","article-title":"Visual loss in orbitofacial neurofibromatosis type 1","volume":"119","author":"Oystreck","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.09.020_bib9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/bjo.77.8.527","article-title":"Orbital plexiform neurofibroma","volume":"77","author":"Ferguson","year":"1993","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.020_bib10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00002341-198804040-00002","article-title":"The surgical management of orbitopalpebral neurofibromatosis","volume":"4","author":"Morax","year":"1988","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2016.09.020_bib11","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.bjps.2005.04.019","article-title":"Remodelling the upper eyelid in the management of orbitopalpebral neurofibromatosis","volume":"58","author":"Marchac","year":"2005","journal-title":"Br J Plast Surg"},{"key":"10.1016\/j.ophtha.2016.09.020_bib12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/01676830600987227","article-title":"Orbitotemporal neurofibromatosis: classification and treatment","volume":"26","author":"Erb","year":"2007","journal-title":"Orbit"},{"key":"10.1016\/j.ophtha.2016.09.020_bib13","first-page":"e49","article-title":"Childhood orbitotemporal neurofibromatosis masked by congenital glaucoma and buphthalmos","volume":"48","author":"Ziakas","year":"2011","journal-title":"J\u00a0Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.ophtha.2016.09.020_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006534-199307000-00001","article-title":"Orbitotemporal neurofibromatosis: classification and treatment","volume":"92","author":"Jackson","year":"1993","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2016.09.020_bib15","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/0002-9394(85)90514-8","article-title":"Localized orbital neurofibromas","volume":"100","author":"Krohel","year":"1985","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.020_bib16","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/eye.2011.336","article-title":"Orbitofacial neurofibromatosis: clinical characteristics and treatment outcome","volume":"26","author":"Chaudhry","year":"2012","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2016.09.020_bib17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ophtha.2003.05.029","article-title":"Orbitotemporal neurofibromatosis. Clinical features and surgical management","volume":"111","author":"Lee","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.09.020_bib18","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0007-1226(03)00172-3","article-title":"The surgical management of childhood orbito-temporal neurofibromatosis","volume":"56","author":"Lee","year":"2003","journal-title":"Br J Plast Surg"},{"key":"10.1016\/j.ophtha.2016.09.020_bib19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00000637-198203000-00008","article-title":"The management of orbitofacial neurofibromatosis","volume":"8","author":"Van der Meulen","year":"1982","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.ophtha.2016.09.020_bib20","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.jcms.2015.06.023","article-title":"Surgical care burden in orbito-temporal neurofibromatosis: multiple procedures and surgical care duration analysis in 47 consecutive adult patients","volume":"43","author":"Pessis","year":"2015","journal-title":"J\u00a0Craniomaxillofac Surg"},{"key":"10.1016\/j.ophtha.2016.09.020_bib21","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","article-title":"Neurofibromatosis type 1: a multidisciplinary approach to care","volume":"13","author":"Hirbe","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ophtha.2016.09.020_bib22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0092-8674(01)00245-8","article-title":"NF1 tumor suppressor gene function: narrowing the GAP","volume":"104","author":"Cichowski","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.ophtha.2016.09.020_bib23","series-title":"Neurofibromatosis Type 1: Molecular and Cellular Biology","first-page":"625","article-title":"Translational\/clinical studies in children and adults with neurofibromatosis type 1","author":"Korf","year":"2012"},{"key":"10.1016\/j.ophtha.2016.09.020_bib24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/(SICI)1098-2264(199903)24:3<283::AID-GCC15>3.0.CO;2-K","article-title":"Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma","volume":"24","author":"Kluwe","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ophtha.2016.09.020_bib25","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1093\/hmg\/9.20.3055","article-title":"Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations","volume":"9","author":"Serra","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ophtha.2016.09.020_bib26","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI60578","article-title":"MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors","volume":"123","author":"Jessen","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ophtha.2016.09.020_bib27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<14::AID-AJMG5>3.0.CO;2-4","article-title":"Hyperactive Ras as a therapeutic target in neurofibromatosis type 1","volume":"89","author":"Weiss","year":"1999","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.ophtha.2016.09.020_bib28","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1158\/0008-5472.CAN-04-4058","article-title":"Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors","volume":"65","author":"Dasgupta","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ophtha.2016.09.020_bib29","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/1535-7163.MCT-07-2335","article-title":"Effective in\u00a0vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors","volume":"7","author":"Johansson","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ophtha.2016.09.020_bib30","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.0503224102","article-title":"The NF1 tumor suppressor critically regulates TSC2 and mTOR","volume":"102","author":"Johannessen","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2016.09.020_bib31","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.4049\/jimmunol.178.4.2527","article-title":"K-ras is critical for modulating multiple c-kit-mediated cellular functions in wild-type and Nf1+\/- mast cells","volume":"178","author":"Khalaf","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ophtha.2016.09.020_bib32","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cell.2008.08.041","article-title":"Nf1-dependent tumors\u00a0require a microenvironment containing Nf1+\/\u2013 and c-kit-dependent bone marrow","volume":"135","author":"Yang","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.ophtha.2016.09.020_bib33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s12307-012-0115-x","article-title":"The plexiform neurofibroma microenvironment","volume":"5","author":"Yang","year":"2012","journal-title":"Cancer Microenviron"},{"key":"10.1016\/j.ophtha.2016.09.020_bib34","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1172\/JCI7610","article-title":"Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models","volume":"105","author":"DeClue","year":"2000","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ophtha.2016.09.020_bib35","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1034\/j.1600-0625.2003.00062.x","article-title":"Expression of angiogenic factors in neurofibromas","volume":"12","author":"Kawachi","year":"2003","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.ophtha.2016.09.020_bib36","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1128\/MCB.17.2.862","article-title":"Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase","volume":"17","author":"Kim","year":"1997","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ophtha.2016.09.020_bib37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ccr.2004.10.016","article-title":"Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis","volume":"7","author":"Ling","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ophtha.2016.09.020_bib38","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e3181bd1326","article-title":"Characteristics of children\u00a0enrolled in treatment trials for NF1-related plexiform neurofibromas","volume":"73","author":"Kim","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ophtha.2016.09.020_bib39","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0022-3476(97)70092-1","article-title":"Prognostic signs in the\u00a0surgical management of plexiform neurofibroma: the Children's Hospital of Philadelphia experience, 1974-1994","volume":"131","author":"Needle","year":"1997","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.ophtha.2016.09.020_bib40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.compmedimag.2004.03.002","article-title":"Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging","volume":"28","author":"Solomon","year":"2004","journal-title":"Comput Med Imaging Graph"},{"key":"10.1016\/j.ophtha.2016.09.020_bib41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.pediatrneurol.2007.01.009","article-title":"Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas","volume":"36","author":"Babovic-Vuksanovic","year":"2007","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ophtha.2016.09.020_bib42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/WNL.0b013e318207b031","article-title":"Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas","volume":"76","author":"Jakacki","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.ophtha.2016.09.020_bib43","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/pbc.24873","article-title":"Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study","volume":"61","author":"Weiss","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ophtha.2016.09.020_bib44","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/pbc.25041","article-title":"Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas","volume":"61","author":"Widemann","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ophtha.2016.09.020_bib45","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/neuonc\/nou004","article-title":"Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas","volume":"16","author":"Widemann","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ophtha.2016.09.020_bib46","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/now158","article-title":"Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas","author":"Jakacki","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ophtha.2016.09.020_bib47","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/neuonc\/nou235","article-title":"Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study","volume":"17","author":"Weiss","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ophtha.2016.09.020_bib48","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1212\/01.wnl.0000435744.57038.af","article-title":"Recommendations for imaging tumor response in neurofibromatosis clinical trials","volume":"81","author":"Dombi","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ophtha.2016.09.020_bib49","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","article-title":"NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight","volume":"68","author":"Dombi","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ophtha.2016.09.020_bib50","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ajmg.a.36312","article-title":"CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies","volume":"164A","author":"Widemann","year":"2014","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.ophtha.2016.09.020_bib51","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jpeds.2013.10.081","article-title":"Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I","volume":"164","author":"Dagalakis","year":"2013","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.ophtha.2016.09.020_bib52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1750-1172-7-75","article-title":"Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1","volume":"7","author":"Nguyen","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ophtha.2016.09.020_bib53","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/gim.2013.30","article-title":"Growth behavior of plexiform neurofibromas after surgery","volume":"15","author":"Nguyen","year":"2013","journal-title":"Genet Med"},{"key":"10.1016\/j.ophtha.2016.09.020_bib54","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3109\/01676831003660689","article-title":"Clinical features and surgical management of orbitotemporal neurofibromatosis: a retrospective interventional case series","volume":"29","author":"Altan-Yaycioglu","year":"2010","journal-title":"Orbit"},{"key":"10.1016\/j.ophtha.2016.09.020_bib55","first-page":"338","article-title":"Ocular motility abnormalities in orbitofacial neurofibromatosis type 1","volume":"18","author":"Oystreck","year":"2014","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.ophtha.2016.09.020_bib56","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.ophtha.2009.04.034","article-title":"Prevalence of amblyopia and strabismus in white and African American children aged 6 through 71 months. The Baltimore Pediatric Eye Disease Study","volume":"116","author":"Friedman","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.09.020_bib57","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00002341-199612000-00006","article-title":"Orbital and eyelid manifestations of neurofibromatosis: a clinical study and literature review","volume":"12","author":"Farris","year":"1996","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2016.09.020_bib58","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s11912-009-0045-z","article-title":"Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors","volume":"11","author":"Widemann","year":"2009","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ophtha.2016.09.020_bib59","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6","article-title":"Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases","volume":"57","author":"Ducatman","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.ophtha.2016.09.020_bib60","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1002\/1097-0142(19810515)47:10<2503::AID-CNCR2820471033>3.0.CO;2-3","article-title":"Malignant schwannoma\u2013clinical characteristics, survival, and response to therapy","volume":"47","author":"Sordillo","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ophtha.2016.09.020_bib61","first-page":"362","article-title":"Neurogenic tumours of the head and neck","volume":"3","author":"Conley","year":"1972","journal-title":"J\u00a0Otolaryngol Soc Aust"},{"key":"10.1016\/j.ophtha.2016.09.020_bib62","series-title":"Benign Eyelid Tumors","author":"Foster","year":"2002"},{"key":"10.1016\/j.ophtha.2016.09.020_bib63","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/00006534-199809010-00005","article-title":"Transcranial correction of orbital neurofibromatosis","volume":"102","author":"Snyder","year":"1998","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2016.09.020_bib64","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1212\/01.WNL.0000042321.94839.78","article-title":"Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1","volume":"60","author":"Gupta","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ophtha.2016.09.020_bib65","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1212\/01.wnl.0000243231.12248.67","article-title":"Phase II trial of pirfenidone in adults with neurofibromatosis type 1","volume":"67","author":"Babovic-Vuksanovic","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ophtha.2016.09.020_bib66","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1517\/13543784.2013.772979","article-title":"Optimizing biologically targeted clinical trials for neurofibromatosis","volume":"22","author":"Gutmann","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ophtha.2016.09.020_bib67","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","article-title":"Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial","volume":"13","author":"Robertson","year":"2012","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1016\/j.ophtha.2016.09.020_bib68","doi-asserted-by":"crossref","first-page":"10018","DOI":"10.1200\/jco.2014.32.15_suppl.10018","article-title":"Phase I study of the MEK1\/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs)","volume":"32","author":"Widemann","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ophtha.2016.09.020_bib69","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1212\/01.wnl.0000435748.79908.c5","article-title":"Conclusions and future directions for the REiNS International Collaboration","volume":"81","author":"Widemann","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ophtha.2016.09.020_bib70","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1212\/01.wnl.0000435745.95155.b8","article-title":"Functional outcome measures for NF1-associated optic pathway glioma clinical trials","volume":"81","author":"Fisher","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ophtha.2016.09.020_bib71","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1212\/01.wnl.0000435746.02780.f6","article-title":"Hearing and facial function outcomes for neurofibromatosis 2 clinical trials","volume":"81","author":"Plotkin","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ophtha.2016.09.020_bib72","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/01.wnl.0000435743.49414.b6","article-title":"Achieving consensus for clinical trials: the REiNS International Collaboration","volume":"81","author":"Plotkin","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ophtha.2016.09.020_bib73","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1212\/01.wnl.0000435747.02780.bf","article-title":"Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials","volume":"81","author":"Wolters","year":"2013","journal-title":"Neurology"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016313525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016313525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T03:57:40Z","timestamp":1568519860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642016313525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0161642016313525"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2016.09.020","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726937165.793527725","asserted-by":"object"}]},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Orbital\/Periorbital Plexiform Neurofibromas in Children with Neurofibromatosis Type 1","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2016.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}